Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging therapies for heart failure.

Amy E Rudolph1, Ellen G McMahon

  • 1Cardiovascular & Metabolic Diseases, Pharmacia Corporation T1G, 800 North Lindbergh Blvd, St. Louis, Missouri 63167, USA.

Expert Opinion on Emerging Drugs
|July 2, 2005
PubMed
Summary

Despite advancements, heart failure (HF) mortality remains high. Future treatments focusing on myocardial remodeling, cell, and gene therapy offer hope for improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

To replicate or not to replicate? Insights and interpretations from a randomized trial duplication initiative.

Journal of comparative effectiveness research·2021
Same author

Lessons learned from a survey of the diagnosis and treatment journeys of postmenopausal women with hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2013
Same author

Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension.

Current medical research and opinion·2011
Same author

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.

Stroke·2009
Same author

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Atherosclerosis·2008
Same author

Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.

Current medical research and opinion·2008

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) continues to have high mortality rates despite current treatments.
  • Existing therapies include diuretics, digitalis, beta-blockers, and renin-angiotensin-aldosterone system inhibitors.
  • Over 300,000 deaths annually in the US are linked to HF.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for heart failure.
  • To highlight the potential of novel molecular targets and disease-modifying approaches.
  • To emphasize the importance of targeting myocardial remodeling for improved HF outcomes.

Main Methods:

  • Review of existing literature on heart failure treatments.
  • Evaluation of preclinical and clinical data for novel therapeutic targets.
  • Discussion of future directions including cell transplantation and gene therapy.

Main Results:

  • Current HF treatments, while extensive, have not significantly reduced mortality.
  • Several novel molecular targets are under investigation, including vasopeptidase, endothelin-1, arginine vasopressin, aldosterone, TNF-alpha, and matrix metalloproteinase inhibitors.
  • Promising future strategies involve cell transplantation, gene therapy, and agents that attenuate myocardial remodeling.

Conclusions:

  • Despite current therapeutic options, heart failure mortality remains a significant clinical challenge.
  • Emerging molecular targets and advanced therapies like cell and gene therapy show promise.
  • Attenuating myocardial remodeling is a key strategy for future heart failure treatment and improved survival.

Related Experiment Videos